TP53 and leukemia: Given that TP53 mutations are typically detected as secondary somatic mutations in t(8;21) AML, and that acute and chronic inhibition of TP53 sometimes show opposing effects [27], the effect of late Trp53 depletion in the established RUNX1-ETO9a leukemia warrants further investigation.